Reaction
Prostate Cancer Recurrent reporting signals
As of the last recalculation, Prostate Cancer Recurrent appears in 606 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is BICALUTAMIDE (PRR 144.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bicalutamide | 58 | 144.5 | 145.0 |
| Abiraterone | 26 | 68.5 | 68.6 |
| Leuprolide Acetate | 89 | 46.0 | 46.1 |
| Goserelin | 17 | 44.7 | 44.8 |
| Enzalutamide | 55 | 35.2 | 35.3 |
| Abiraterone Acetate | 39 | 34.7 | 34.8 |
| Docetaxel Anhydrous | 38 | 20.6 | 20.6 |
| Docetaxel | 38 | 20.6 | 20.6 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 7 | 18.4 | 18.5 |
| Relugolix | 10 | 14.8 | 14.8 |
| Apalutamide | 5 | 14.7 | 14.7 |
| Olaparib | 6 | 9.9 | 9.9 |